Nesvategrast

DB19337InvestigationalSmall molecule

Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

Mechanism: Pharmacologically active on Integrin beta-3, Integrin alpha-V, and Integrin beta-6
Curator reviewed
Formula / weight: C₂₃H₂₇F₂N₅O₄ · 475.497 g/mol (avg)
Also known as: (s)-3-(6-(difluoromethoxy)pyridin-3-yl)-3-(oxo-2-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoate · 3-Pyridinepropanoic acid, 6-(difluoromethoxy)-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)- · βS)-6-(Difluoromethoxy)-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-3-pyridinepropanoic acid
Code names: CS-0063976 · DA-57817 · HY-117133 · OT-166 · SF0166 · SF-0166 FREE ACID

Resolves to

Compound

Structure

InChIKeyIGUVQCZYMKVWFL-SFHVURJKSA-NSMILESOC(=O)C[C@H](N1CCN(CCCC2=CC=C3CCCNC3=N2)C1=O)C1=CC=C(OC(F)F)N=C1

Targets

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nesvategrast, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.